Abstract
Melamine (2,4,6-triamino-1,3,5-triazine) was first synthesized by Liebig in 1834 and its industrial application, starting with the development of melamine formaldehyde resins in the late 1930ies, has boomed since. In the last 80 years a vast number of different melamine derivatives have been prepared in order to provide structures for applications such as polymers, medicinal drugs, or biologically active compounds. It is the purpose of this review to give an overview on the currently available melamine derivatives and the synthesis strategies leading to their formation.
Keywords: Cyanuric chloride, Melamine, Melamine derivatives, Synthesis, s-Triazines, Triamino-s-triazine
Current Organic Synthesis
Title:Melamine Derivatives - A Review on Synthesis and Application
Volume: 9 Issue: 3
Author(s): Klaus Bretterbauer and Clemens Schwarzinger
Affiliation:
Keywords: Cyanuric chloride, Melamine, Melamine derivatives, Synthesis, s-Triazines, Triamino-s-triazine
Abstract: Melamine (2,4,6-triamino-1,3,5-triazine) was first synthesized by Liebig in 1834 and its industrial application, starting with the development of melamine formaldehyde resins in the late 1930ies, has boomed since. In the last 80 years a vast number of different melamine derivatives have been prepared in order to provide structures for applications such as polymers, medicinal drugs, or biologically active compounds. It is the purpose of this review to give an overview on the currently available melamine derivatives and the synthesis strategies leading to their formation.
Export Options
About this article
Cite this article as:
Bretterbauer Klaus and Schwarzinger Clemens, Melamine Derivatives - A Review on Synthesis and Application, Current Organic Synthesis 2012; 9 (3) . https://dx.doi.org/10.2174/157017912801270612
DOI https://dx.doi.org/10.2174/157017912801270612 |
Print ISSN 1570-1794 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6271 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML
Current Pharmaceutical Biotechnology Towards a Gene Therapy Clinical Trial for Epidermolysis Bullosa
Reviews on Recent Clinical Trials Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Recent Advances in Positron Emission Tomography (PET) Imaging of Biomolecules: From Chemical Labeling to Cancer Diagnostics
Mini-Reviews in Organic Chemistry Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Role of microRNAs in Vascular Remodeling
Current Molecular Medicine New Derivatives of BM212: A Class of Antimycobacterial Compounds Based on the Pyrrole Ring as a Scaffold
Mini-Reviews in Medicinal Chemistry Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Anticancer and Antibacterial Activity of Hyperforin and Its Derivatives
Anti-Cancer Agents in Medicinal Chemistry New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer
Current Pharmaceutical Design Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Editorial [Hot topic: Selected New Developments in Oncology (Guest Editors: Jos H. Beijnen and Jan H.M. Schellens)]
Current Clinical Pharmacology Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets Clinical Application of Lentiviral Vectors – Concepts and Practice
Current Gene Therapy Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse
Anti-Cancer Agents in Medicinal Chemistry Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles
Current Medicinal Chemistry MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA Genetic Control of Sister Chromatid Recombination: The Role of Radiation Repair (RAD) Genes
Current Genomics